Early research suggests patches might lower some gastrointestinal side effects by releasing medication more steadily, but this has not been confirmed in human studies
The timeline and magnitude of these changes depend on the specific medication, duration of treatment, and individual patient factors
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al
This product has not been evaluated by the FDA for safety or effectiveness
Customers can access the compounded GLP-1 medications via a prescription from a licensed health-care provider on the Hims & Hers platform
Based on Phase 2 trial protocols by Eli Lilly, initiation was typically at 2 mg once weekly via subcutaneous injection, with gradual dose escalation thereafter